{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T03:19:08Z","timestamp":1792293548081,"version":"4.4.0"},"reference-count":79,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["cancertreatmentreviews.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.ctrv.2023.102560","type":"journal-article","created":{"date-parts":[[2023,4,17]],"date-time":"2023-04-17T20:38:42Z","timestamp":1681763922000},"page":"102560","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":54,"special_numbering":"C","title":["Targeting neuroendocrine tumors with octreotide and lanreotide: Key points for clinical practice from NET specialists"],"prefix":"10.1016","volume":"117","author":[{"given":"A.","family":"La Salvia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Modica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.E.","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Spada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Rinzivillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Panzuto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Faggiano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Cinieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Fazio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctrv.2023.102560_b0005","unstructured":"Rindi G, Moch H, McCluggage WG, et al Neuroendocrine neoplasms, non-endocrine organs. In: WHO Classification of Tumours Editorial Board, editor. WHO classification of tumours endocrine and neuroendocrine tumours. 5th ed. Lyon, France: International Agency for Research on Cancer (IARC); 2022."},{"issue":"2","key":"10.1016\/j.ctrv.2023.102560_b0010","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1111\/his.13975","article-title":"The 2019 WHO classification of tumours of the digestive system","volume":"76","author":"Nagtegaal","year":"2020","journal-title":"Histopathology"},{"issue":"1","key":"10.1016\/j.ctrv.2023.102560_b0015","doi-asserted-by":"crossref","first-page":"3407","DOI":"10.1038\/s41467-019-11276-9","article-title":"Integrative and comparative genomic analyses identify clinically relevant pulmonary carcinoid groups and unveil the supra-carcinoids","volume":"10","author":"Alcala","year":"2019","journal-title":"Nat Commun"},{"issue":"3","key":"10.1016\/j.ctrv.2023.102560_b0020","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1210\/er.2003-0014","article-title":"The diagnosis and medical management of advanced neuroendocrine tumors","volume":"25","author":"Kaltsas","year":"2004","journal-title":"Endocr Rev"},{"issue":"3","key":"10.1016\/j.ctrv.2023.102560_b0025","doi-asserted-by":"crossref","first-page":"R153","DOI":"10.1530\/ERC-13-0125","article-title":"Incidence of gastroenteropancreatic neuroendocrine tumours: a systematic review of the literature","volume":"21","author":"Fraenkel","year":"2014","journal-title":"Endocr Relat Cancer"},{"issue":"10","key":"10.1016\/j.ctrv.2023.102560_b0030","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1001\/jamaoncol.2017.0589","article-title":"Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States","volume":"3","author":"Dasari","year":"2017","journal-title":"JAMA Oncol"},{"issue":"18","key":"10.1016\/j.ctrv.2023.102560_b0035","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1200\/JCO.2007.15.4377","article-title":"One hundred years after \u2018carcinoid\u2019: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States","volume":"26","author":"Yao","year":"2008","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.ctrv.2023.102560_b0040","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1530\/EC-16-0043","article-title":"A Delphic consensus assessment: imaging and biomarkers in gastroenteropancreatic neuroendocrine tumor disease management","volume":"5","author":"Oberg","year":"2016","journal-title":"Endocr Connect"},{"issue":"12","key":"10.1016\/j.ctrv.2023.102560_b0045","doi-asserted-by":"crossref","first-page":"3049","DOI":"10.3390\/ijms20123049","article-title":"Somatostatin Analogues in the Treatment of Neuroendocrine Tumors: Past, Present and Future","volume":"20","author":"Stueven","year":"2019","journal-title":"Int J Mol Sci"},{"issue":"3","key":"10.1016\/j.ctrv.2023.102560_b0050","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.yfrne.2013.07.005","article-title":"Somatostatin receptors: from signaling to clinical practice","volume":"34","author":"Theodoropoulou","year":"2013","journal-title":"Front Neuroendocrinol"},{"issue":"11","key":"10.1016\/j.ctrv.2023.102560_b0055","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1111\/j.1582-4934.2010.01125.x","article-title":"Somatostatin receptor biology in neuroendocrine and pituitary tumours: part 1\u2013molecular pathways","volume":"14","author":"Cakir","year":"2010","journal-title":"J Cell Mol Med"},{"issue":"4","key":"10.1016\/j.ctrv.2023.102560_b0060","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1124\/pr.117.015388","article-title":"International Union of Basic and Clinical Pharmacology. CV. Somatostatin Receptors: Structure, Function, Ligands, and New Nomenclature","volume":"70","author":"G\u00fcnther","year":"2018","journal-title":"Pharmacol Rev"},{"issue":"3","key":"10.1016\/j.ctrv.2023.102560_b0065","first-page":"238","article-title":"The incidence of somatostatin receptors in human neoplasms in the light of ex vivo-in vitro studies","volume":"57","author":"Pawlikowski","year":"2006","journal-title":"Endokrynol Pol"},{"issue":"9","key":"10.1016\/j.ctrv.2023.102560_b0070","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1007\/s002590100598","article-title":"Erratum to: Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands","volume":"28","author":"Reubi","year":"2001","journal-title":"Eur J Nucl Med"},{"issue":"12","key":"10.1016\/j.ctrv.2023.102560_b0075","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1093\/annonc\/mdl105","article-title":"Rationale for the use of somatostatin analogs as antitumor agents","volume":"17","author":"Susini","year":"2006","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.ctrv.2023.102560_b0080","doi-asserted-by":"crossref","first-page":"513","DOI":"10.3109\/00365521.2015.1115117","article-title":"Somatostatin analogues in functioning gastroenteropancreatic neuroendocrine tumours: literature review, clinical recommendations and schedules","volume":"51","author":"Massironi","year":"2016","journal-title":"Scand J Gastroenterol"},{"issue":"9","key":"10.1016\/j.ctrv.2023.102560_b0085","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1517\/13543780903176399","article-title":"Somatostatin and somatostatin receptors: implications for neoplastic growth and cancer biology","volume":"18","author":"Msaouel","year":"2009","journal-title":"Expert Opin Investig Drugs"},{"issue":"3","key":"10.1016\/j.ctrv.2023.102560_b0090","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.tem.2013.11.003","article-title":"Somatostatin analogs: does pharmacology impact antitumor efficacy?","volume":"25","author":"Chalabi","year":"2014","journal-title":"Trends Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.ctrv.2023.102560_b0095","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.anclin.2017.01.021","article-title":"Pharmacology of Octreotide: Clinical Implications for Anesthesiologists and Associated Risks","volume":"35","author":"Borna","year":"2017","journal-title":"Anesthesiol Clin"},{"issue":"7","key":"10.1016\/j.ctrv.2023.102560_b0100","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1177\/0091270005277936","article-title":"Long-acting octreotide and prolonged-release lanreotide formulations have different pharmacokinetic profiles","volume":"45","author":"Astruc","year":"2005","journal-title":"J Clin Pharmacol"},{"issue":"5","key":"10.1016\/j.ctrv.2023.102560_b0105","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1177\/00912700022009242","article-title":"Pharmacokinetics, pharmacodynamics, and safety of microencapsulated octreotide acetate in healthy subjects","volume":"40","author":"Chen","year":"2000","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.ctrv.2023.102560_b0110","unstructured":"Somatuline\u00ae Autogel\u00ae lanreotide injection [product monograph]. Ipsen Biopharm Limited, UK, 2015."},{"issue":"2","key":"10.1016\/j.ctrv.2023.102560_b0115","doi-asserted-by":"crossref","first-page":"77","DOI":"10.2165\/00024677-200403020-00002","article-title":"Lanreotide Autogel for acromegaly: a new addition to the treatment armamentarium","volume":"3","author":"Ciccarelli","year":"2004","journal-title":"Treat Endocrinol"},{"issue":"10","key":"10.1016\/j.ctrv.2023.102560_b0120","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1016\/j.metabol.2005.04.014","article-title":"Pharmacokinetics and population pharmacodynamic analysis of lanreotide Autogel","volume":"54","author":"Cendros","year":"2005","journal-title":"Metabolism"},{"issue":"3","key":"10.1016\/j.ctrv.2023.102560_b0125","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1159\/000471880","article-title":"ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms: Systemic Therapy - Biotherapy and Novel Targeted Agents","volume":"105","author":"Pavel","year":"2017","journal-title":"Neuroendocrinology"},{"issue":"7","key":"10.1016\/j.ctrv.2023.102560_b0130","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/j.annonc.2020.03.304","article-title":"Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"31","author":"Pavel","year":"2020","journal-title":"Ann Oncol"},{"issue":"28","key":"10.1016\/j.ctrv.2023.102560_b0135","doi-asserted-by":"crossref","first-page":"4656","DOI":"10.1200\/JCO.2009.22.8510","article-title":"Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group","volume":"27","author":"Rinke","year":"2009","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ctrv.2023.102560_b0140","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1056\/NEJMoa1316158","article-title":"Lanreotide in metastatic enteropancreatic neuroendocrine tumors","volume":"371","author":"Caplin","year":"2014","journal-title":"N Engl J Med"},{"issue":"9808","key":"10.1016\/j.ctrv.2023.102560_b0145","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1016\/S0140-6736(11)61742-X","article-title":"Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study","volume":"378","author":"Pavel","year":"2011","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.ctrv.2023.102560_b0150","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa1607427","article-title":"Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors","volume":"376","author":"Strosberg","year":"2017","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.ctrv.2023.102560_b0155","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1097\/MPA.0000000000001597","article-title":"The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Medical Management of Pancreatic Neuroendocrine Tumors","volume":"49","author":"Halfdanarson","year":"2020","journal-title":"Pancreas"},{"issue":"2","key":"10.1016\/j.ctrv.2023.102560_b0160","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1159\/000353785","article-title":"Impact of octreotide long-acting release on tumour growth control as a first-line treatment in neuroendocrine tumours of pancreatic origin","volume":"98","author":"Jann","year":"2013","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.ctrv.2023.102560_b0165","unstructured":"Annals of Oncology (2021) 32 (suppl_5): S906-S920. 10.1016\/annonc\/annonc678."},{"issue":"4","key":"10.1016\/j.ctrv.2023.102560_b0170","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.cllc.2016.11.004","article-title":"Outcome Analysis of First-line Somatostatin Analog Treatment in Metastatic Pulmonary Neuroendocrine Tumors and Prognostic Significance of 18FDG-PET\/CT","volume":"18","author":"Bongiovanni","year":"2017","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.ctrv.2023.102560_b0175","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.669484","article-title":"Outcome of Patients With Metastatic Lung Neuroendocrine Tumors Submitted to First Line Monotherapy With Somatostatin Analogs","volume":"12","author":"Lenotti","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"5","key":"10.1016\/j.ctrv.2023.102560_b0180","doi-asserted-by":"crossref","first-page":"5538","DOI":"10.18632\/oncotarget.6686","article-title":"Somatostatin analogues according to Ki67 index in neuroendocrine tumours: an observational retrospective-prospective analysis from real life","volume":"7","author":"Faggiano","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.ctrv.2023.102560_b0185","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1200\/JCO.2021.39.3_suppl.360","article-title":"A phase II\/III randomized double-blind study of octreotide acetate LAR with axitinib versus octreotide acetate LAR with placebo in patients with advanced G1\u2013G2 NETs of non-pancreatic origin (AXINET trial-GETNE-1107)","volume":"39: 3_suppl","author":"Garcia-Carbonero","year":"2021","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ctrv.2023.102560_b0190","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s40618-021-01642-0","article-title":"Gastroenteropancreatic grade 3 neuroendocrine tumors: a single entity or a heterogeneous group?","volume":"45","author":"Laffi","year":"2022","journal-title":"A retrospective analysis J Endocrinol Invest"},{"issue":"5","key":"10.1016\/j.ctrv.2023.102560_b0195","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1530\/ERC-13-0027","article-title":"Are G3 ENETS neuroendocrine neoplasms heterogeneous?","volume":"20","author":"V\u00e9layoudom-C\u00e9phise","year":"2013","journal-title":"Endocr Relat Cancer"},{"issue":"1","key":"10.1016\/j.ctrv.2023.102560_b0200","doi-asserted-by":"crossref","first-page":"17947","DOI":"10.1038\/s41598-021-97247-x","article-title":"Well-differentiated gastroenteropancreatic G3 NET: findings from a large single centre cohort","volume":"11","author":"Lithgow","year":"2021","journal-title":"Sci Rep"},{"issue":"2","key":"10.1016\/j.ctrv.2023.102560_b0205","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1159\/000443170","article-title":"ENETS Consensus Guidelines Update for Neuroendocrine Neoplasms of the Jejunum and Ileum","volume":"103","author":"Niederle","year":"2016","journal-title":"Neuroendocrinology"},{"issue":"7","key":"10.1016\/j.ctrv.2023.102560_b0210","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1200\/JCO.2010.33.2056","article-title":"Future directions in the treatment of neuroendocrine tumors: consensus report of the National Cancer Institute Neuroendocrine Tumor clinical trials planning meeting","volume":"29","author":"Kulke","year":"2011","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.ctrv.2023.102560_b0215","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1002\/jso.25896","article-title":"Adjuvant therapy following resection of gastroenteropancreatic neuroendocrine tumors provides no recurrence or survival benefit","volume":"121","author":"Barrett","year":"2020","journal-title":"J Surg Oncol"},{"issue":"7","key":"10.1016\/j.ctrv.2023.102560_b0220","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/j.annonc.2020.03.304","article-title":"Supplementary Material Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"31","author":"Pavel","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2023.102560_b0225","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.ejca.2022.07.033","article-title":"Lanreotide as maintenance therapy after first-line treatment in patients with non-resectable duodeno-pancreatic neuroendocrine tumours: An international double-blind, placebo-controlled randomised phase II trial - Prodige 31 REMINET: An FFCD study","volume":"175","author":"Lepage","year":"2022","journal-title":"Eur J Cancer"},{"issue":"19","key":"10.1016\/j.ctrv.2023.102560_b0230","doi-asserted-by":"crossref","first-page":"4672","DOI":"10.1158\/1078-0432.CCR-18-0947","article-title":"The Role of Adding Somatostatin Analogues to Peptide Receptor Radionuclide Therapy as a Combination and Maintenance Therapy","volume":"24","author":"Yordanova","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.ctrv.2023.102560_b0235","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1507\/endocrj.EJ16-0219","article-title":"Does combination of \u2018cold\u2019 and \u2018hot\u2019 somatostatin analogs prolong survival of patients with neuroendocrine neoplasms?","volume":"64","author":"Sowa-Staszczak","year":"2017","journal-title":"Endocr J"},{"issue":"11","key":"10.1016\/j.ctrv.2023.102560_b0240","doi-asserted-by":"crossref","first-page":"3841","DOI":"10.1007\/s00259-022-05792-y","article-title":"In patients with well-differentiated neuroendocrine tumours, there is no apparent benefit of somatostatin analogues after disease control by peptide receptor radionuclide therapy","volume":"49","author":"Sygu\u0142a","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"10.1016\/j.ctrv.2023.102560_b0245","doi-asserted-by":"crossref","first-page":"845","DOI":"10.21037\/jgo-20-292","article-title":"Octreotide long-acting release (LAR) in combination with other therapies for treatment of neuroendocrine neoplasia: a systematic review","volume":"12","author":"Rinzivillo","year":"2021","journal-title":"J Gastrointest Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2023.102560_b0250","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1200\/JCO.2009.24.2669","article-title":"Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial","volume":"28","author":"Yao","year":"2010","journal-title":"J Clin Oncol"},{"issue":"16","key":"10.1016\/j.ctrv.2023.102560_b0255","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1002\/cncr.28726","article-title":"Everolimus in combination with octreotide long-acting repeatable in a first-line setting for patients with neuroendocrine tumors: an ITMO group study","volume":"120","author":"Bajetta","year":"2014","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.ctrv.2023.102560_b0260","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1159\/000479587","article-title":"Everolimus in Combination with Octreotide Long-Acting Repeatable in a First-Line Setting for Patients with Neuroendocrine Tumors: A 5-Year Update","volume":"106","author":"Bajetta","year":"2018","journal-title":"Neuroendocrinology"},{"issue":"7","key":"10.1016\/j.ctrv.2023.102560_b0265","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1530\/ERC-20-0492","article-title":"Target therapies plus somatostatin analogs in NETs: a network meta-analysis","volume":"28","author":"Pusceddu","year":"2021","journal-title":"Endocr Relat Cancer"},{"issue":"Supplement 6","key":"10.1016\/j.ctrv.2023.102560_b0270","first-page":"vi136","article-title":"Combined lanreotide autogel and temozolomide therapy in progressive neuroendocrine tumours: the SONNET study","volume":"27","author":"H\u00f6rsch","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2023.102560_b0275","article-title":"Efficacy and Safety of Lanreotide Autogel and Temozolomide Combination Therapy in Progressive Thoracic Neuroendocrine Tumors (carcinoid): Results from the Phase 2 ATLANT Study","author":"Ferolla","year":"2022","journal-title":"Neuroendocrinology"},{"issue":"4","key":"10.1016\/j.ctrv.2023.102560_b0280","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.annonc.2021.01.003","article-title":"Lung and thymic carcinoids: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up\u2606","volume":"32","author":"Baudin","year":"2021","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.ctrv.2023.102560_b0285","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1093\/annonc\/mdv041","article-title":"Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids","volume":"26","author":"Caplin","year":"2015","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.ctrv.2023.102560_b0290","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1210\/jc.2018-01931","article-title":"Somatostatin Receptor Expression Is Associated With Metastasis and Patient Outcome in Pulmonary Carcinoid Tumors","volume":"104","author":"Vesterinen","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"10.1016\/j.ctrv.2023.102560_b0295","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1634\/theoncologist.2018-0520","article-title":"Treatment Patterns and Clinical Outcomes in Advanced Lung Neuroendocrine Tumors in Real-World Settings: A Multicenter Retrospective Chart Review Study","volume":"24","author":"Dasari","year":"2019","journal-title":"Oncologist"},{"issue":"5","key":"10.1016\/j.ctrv.2023.102560_b0300","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1159\/000486282","article-title":"Real-World Treatment Patterns for Lung Neuroendocrine Tumors: A Claims Database Analysis","volume":"94","author":"Broder","year":"2018","journal-title":"Oncology"},{"key":"10.1016\/j.ctrv.2023.102560_b0305","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.ejca.2016.11.034","article-title":"Antitumour activity of somatostatin analogues in sporadic, progressive, metastatic pulmonary carcinoids","volume":"75","author":"Sullivan","year":"2017","journal-title":"Eur J Cancer"},{"issue":"4","key":"10.1016\/j.ctrv.2023.102560_b0310","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1378\/chest.12-1108","article-title":"Everolimus plus octreotide long-acting repeatable in patients with advanced lung neuroendocrine tumors: analysis of the phase 3, randomized, placebo-controlled RADIANT-2 study","volume":"143","author":"Fazio","year":"2013","journal-title":"Chest"},{"issue":"7","key":"10.1016\/j.ctrv.2023.102560_b0315","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1007\/s11864-022-00983-z","article-title":"High-Dose Somatostatin Analogs for the Treatment of Neuroendocrine Neoplasms: where are we Now?","volume":"23","author":"Alonso-Gordoa","year":"2022","journal-title":"Curr Treat Options Oncol"},{"key":"10.1016\/j.ctrv.2023.102560_b0320","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.ejca.2021.06.056","article-title":"Efficacy and safety of high-dose lanreotide autogel in patients with progressive pancreatic or midgut neuroendocrine tumours: CLARINET FORTE phase 2 study results","volume":"157","author":"Pavel","year":"2021","journal-title":"Eur J Cancer"},{"issue":"3","key":"10.1016\/j.ctrv.2023.102560_b0325","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1007\/s12020-017-1360-z","article-title":"Escalated-dose somatostatin analogues for antiproliferative effect in GEPNETS: a systematic review","volume":"57","author":"Chan","year":"2017","journal-title":"Endocrine"},{"issue":"1","key":"10.1016\/j.ctrv.2023.102560_b0330","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgz035","article-title":"Nonconventional Doses of Somatostatin Analogs in Patients With Progressing Well-Differentiated Neuroendocrine Tumor","volume":"105","author":"Lamberti","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"20","key":"10.1016\/j.ctrv.2023.102560_b0335","doi-asserted-by":"crossref","first-page":"6127","DOI":"10.3390\/jcm11206127","article-title":"The Antiproliferative Activity of High-Dose Somatostatin Analogs in Gastro-Entero-Pancreatic Neuroendocrine Tumors: A Systematic Review and Meta-Analysis","volume":"11","author":"Panzuto","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.ctrv.2023.102560_b0340","doi-asserted-by":"crossref","unstructured":"Fazio N., Spada F. Real-word analysis on the use of somatostatin analogs (SSAs) in patients with neuroendocrine neoplasms (NENs): results of a survey conducted by the Italian Society of Medical Oncology (AIOM). AIOM annual conference 2016.","DOI":"10.1093\/annonc\/mdw345.25"},{"issue":"1","key":"10.1016\/j.ctrv.2023.102560_b0345","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1210\/er.2000-0001","article-title":"The pathophysiological consequences of somatostatin receptor internalization and resistance","volume":"24","author":"Hofland","year":"2003","journal-title":"Endocr Rev"},{"issue":"5","key":"10.1016\/j.ctrv.2023.102560_b0350","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1530\/EJE-07-0383","article-title":"Beneficial effect of dose escalation of octreotide-LAR as first-line therapy in patients with acromegaly","volume":"157","author":"Colao","year":"2007","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"10.1016\/j.ctrv.2023.102560_b0355","first-page":"326","article-title":"Shortened interval of long-acting octreotide administration is effective in patients with well-differentiated neuroendocrine carcinomas in progression on standard doses","volume":"35","author":"Ferolla","year":"2012","journal-title":"J Endocrinol Invest"},{"issue":"10","key":"10.1016\/j.ctrv.2023.102560_b0360","first-page":"4127","article-title":"High-dose octreotide acetate for management of gastroenteropancreatic neuroendocrine tumors","volume":"29","author":"Chadha","year":"2009","journal-title":"Anticancer Res"},{"issue":"3","key":"10.1016\/j.ctrv.2023.102560_b0365","first-page":"81","article-title":"Above-Label Doses of Octreotide-LAR in Patients With Metastatic Small Intestinal Carcinoid Tumors","volume":"6","author":"Strosberg","year":"2013","journal-title":"Gastrointest Cancer Res"},{"issue":"6","key":"10.1016\/j.ctrv.2023.102560_b0370","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1002\/cam4.435","article-title":"Association of dose escalation of octreotide long-acting release on clinical symptoms and tumor markers and response among patients with neuroendocrine tumors","volume":"4","author":"Al-Efraij","year":"2015","journal-title":"Cancer Med"},{"issue":"4","key":"10.1016\/j.ctrv.2023.102560_b0375","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1080\/14740338.2021.1881478","article-title":"Exocrine pancreatic insufficiency and somatostatin analogs in patients with neuroendocrine neoplasia","volume":"20","author":"Panzuto","year":"2021","journal-title":"Expert Opin Drug Saf"},{"issue":"3","key":"10.1016\/j.ctrv.2023.102560_b0380","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1080\/14740338.2021.1867097","article-title":"Comparative safety review of the current therapies for gastroenteropancreatic neuroendocrine tumors","volume":"20","author":"Koffas","year":"2021","journal-title":"Expert Opin Drug Saf"},{"issue":"9","key":"10.1016\/j.ctrv.2023.102560_b0385","doi-asserted-by":"crossref","first-page":"e1533","DOI":"10.1200\/OP.22.00055","article-title":"A Randomized Trial Evaluating Patient Experience and Preference Between Octreotide Long-Acting Release and Lanreotide for Treatment of Well-Differentiated Neuroendocrine Tumors","volume":"18","author":"Raj","year":"2022","journal-title":"JCO Oncol Pract"},{"issue":"4","key":"10.1016\/j.ctrv.2023.102560_b0390","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1007\/s12325-020-01255-8","article-title":"Evaluation of Nurse Preferences Between the Lanreotide Autogel New Syringe and the Octreotide Long-Acting Release Syringe: An International Simulated-Use Study (PRESTO)","volume":"37","author":"Adelman","year":"2020","journal-title":"Adv Ther"},{"key":"10.1016\/j.ctrv.2023.102560_b0395","first-page":"1","article-title":"PRESTO 2: An International Survey to Evaluate Patients\u2019 Injection Experiences with the Latest Devices\/Formulations of Long-Acting Somatostatin Analog Therapies for Neuroendocrine Tumors or Acromegaly","volume":"11","author":"O\u2019Toole","year":"2022","journal-title":"Adv Ther"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737223000518?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737223000518?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T09:28:58Z","timestamp":1759656538000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737223000518"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":79,"alternative-id":["S0305737223000518"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2023.102560","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting neuroendocrine tumors with octreotide and lanreotide: Key points for clinical practice from NET specialists","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2023.102560","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102560"}}